Estimated reading time: 0 minutes, 37 seconds

Facing the natural expiration of the patent on its highly profitable lung-cancer treatment Alimta, Eli Lily this month went to trial to defend a follow-on patent for the treatment.

 

The follow-on patent would cover not only Alimta's basic compound but a method of administering that drug along with certain vitamins designed to mitigate side effects. So The Wall Street Journal reports.

 

Defending “secondary patents” like the patent on Alimta's vitamin regimen is a way for Big Pharma companies to extend their exclusive rights to sell successful drugs. However, generic-drug companies have historically had significant success arguing that such follow-on patents should be struck down because their claims were anticipated by prior, publicly available research.

 

Read the full article from The Wall Street Journal here.

Last modified on Monday, 26 August 2013
Read 3189 times
Rate this item
(0 votes)
Tagged under

Visit other PMG Sites:

click me
PMG360 is committed to protecting the privacy of the personal data we collect from our subscribers/agents/customers/exhibitors and sponsors. On May 25th, the European's GDPR policy will be enforced. Nothing is changing about your current settings or how your information is processed, however, we have made a few changes. We have updated our Privacy Policy and Cookie Policy to make it easier for you to understand what information we collect, how and why we collect it.
Ok Decline